Skip to content

PolitiKit

Lobbying by Apotex Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Apotex Inc.

Meetings this Parliament
10
With MPs
3
Since Nov 2021
10
Active registrations
1

Most recent reported meeting: Sep 28, 2026.

Registrations in effect

In-house (corporation) In effect since Sep 28, 2026

Filed by Martin Arès, President, Apotex Canada and Rest of World (ROW)

Lobbyists

  • Adriana Valdes Campos · Director, Government Affairs, PR & Communication
  • Andrew Casey · VP, Government Affairs & Policy
  • André Luiz Soresini · Vice President & General Manager, LATAM
  • Chris Fournier · VP Market Access and Government Relations
  • Francesco Tallarico · Chief Legal Officer
  • Martin Arès · President, Apotex Canada and Rest of World (ROW)

Institutions they may lobby: Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Innovation, Science and Economic Development Canada (ISED), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC)

What they're lobbying on (3)
  • Pharmaceutical research & development -support for R&D in Canada.
  • Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing.
  • Pharmaceutical policy: Ongoing interactions related to increased and sustainable utilization of cost-saving generic and biosimilar medicines, and a predictable and viable business environment for generic medicines.

Registration 953865-452-35. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by Martin Arès (6), Raymond Shelley (4).

  • Reported by Martin Arès · In-house (corporation)

    Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing.

    Official report

  • Reported by Martin Arès · In-house (corporation)

    • Frances Anne Watt-Gallardo · Assistant Director, Immigration, Refugees and Citizenship Canada (IRCC)
    • Kulvinder Vaid · Outreach Officer, Immigration, Refugees and Citizenship Canada (IRCC)
    Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing.

    Official report

  • Reported by Martin Arès · In-house (corporation)

    • Mélanie Joly · Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
    Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing. Read more

    Pharmaceutical research & development -support for R&D in Canada.

    Official report

  • Reported by Martin Arès · In-house (corporation)

    • Alex Axiotis-Perez · Deputy Chief of Staff & Director of Operations, Privy Council Office (PCO)
    • Galen Richardson · Director of Stakeholder Relations, Privy Council Office (PCO)
    Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing.

    Official report

  • Reported by Martin Arès · In-house (corporation)

    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Pharmaceutical policy: Ongoing interactions related to increased and sustainable utilization of cost-saving generic and biosimilar medicines, and a predictable and viable business environment for generic medicines. Read more

    Official report

  • Reported by Martin Arès · In-house (corporation)

    • Deepa Murthy · Assistant Director, Immigration, Refugees and Citizenship Canada (IRCC)
    • Frances Anne Watt-Gallardo · Assistant Director, Immigration, Refugees and Citizenship Canada (IRCC)
    • Kulvinder Vaid · Program Manager, Immigration, Refugees and Citizenship Canada (IRCC)
    Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing.

    Official report

  • Reported by Raymond Shelley · In-house (corporation)

    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    Pharmaceutical policy: Ongoing interactions related to increased and sustainable utilization of cost-saving generic and biosimilar medicines, and a predictable and viable business environment for generic medicines. Read more

    Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing.

    Official report

  • Reported by Raymond Shelley · In-house (corporation)

    and 4 more
    • Guillaume Couillard · Director General, Patented Medicine Prices Review Board (PMPRB)
    • Rodrigo Arancibia · Sr Director, Innovation, Science and Economic Development Canada (ISED)
    • Loris Mirella · Director - Intellectual Property Trade Policy, Global Affairs Canada (GAC)
    • Arianne Reza · Deputy Minister of Public Services and Procurement, Public Services and Procurement Canada (PSPC)
    Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing. Read more

    Pharmaceutical policy: Ongoing interactions related to increased and sustainable utilization of cost-saving generic and biosimilar medicines, and a predictable and viable business environment for generic medicines.

    Official report

  • Reported by Raymond Shelley · In-house (corporation)

    • Yash Nanda · Policy Advisor, Prime Minister's Office (PMO)
    Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing. Read more

    Pharmaceutical policy: Ongoing interactions related to increased and sustainable utilization of cost-saving generic and biosimilar medicines, and a predictable and viable business environment for generic medicines.

    Official report

  • Reported by Raymond Shelley · In-house (corporation)

    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing. Read more

    Pharmaceutical research & development -support for R&D in Canada.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.